<DOC>
	<DOCNO>NCT01375764</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week subcutaneous evolocumab ( AMG 145 ) , compare ezetimibe , percent change baseline low-density lipoprotein cholesterol ( LDL-C ) patient hypercholesterolemia unable tolerate effective dose statin .</brief_summary>
	<brief_title>Goal Achievement After Utilizing Anti-PCSK9 Antibody Statin Intolerant Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male female ≥ 18 ≤ 75 year age On statin low dose statin stable dose least 4 week Lipid lower therapy stable prior enrollment Fasting triglyceride must &lt; 400 mg/dL . Subject LDLC goal New York Heart Association ( NYHA ) III IV heart failure know leave ventricular ejection fraction &lt; 30 % Uncontrolled cardiac arrhythmia Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month prior randomization Type 1 diabetes newly diagnose type 2 diabetes ( HbA1c &gt; 8.5 % ) Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Proprotein convertase subtilisin/kexin type 9 ( PCSK9 )</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Raised Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>Statin intolerant</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>